Hookipa Change Receivables vs Change In Cash Analysis
HOOK Stock | USD 2.41 0.13 5.12% |
Hookipa Pharma financial indicator trend analysis is much more than just examining Hookipa Pharma latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Hookipa Pharma is a good investment. Please check the relationship between Hookipa Pharma Change Receivables and its Change In Cash accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.
Change Receivables vs Change In Cash
Change Receivables vs Change In Cash Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Hookipa Pharma Change Receivables account and Change In Cash. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Hookipa Pharma's Change Receivables and Change In Cash is -0.41. Overlapping area represents the amount of variation of Change Receivables that can explain the historical movement of Change In Cash in the same time period over historical financial statements of Hookipa Pharma, assuming nothing else is changed. The correlation between historical values of Hookipa Pharma's Change Receivables and Change In Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change Receivables of Hookipa Pharma are associated (or correlated) with its Change In Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change In Cash has no effect on the direction of Change Receivables i.e., Hookipa Pharma's Change Receivables and Change In Cash go up and down completely randomly.
Correlation Coefficient | -0.41 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Change Receivables
The difference in the amount of accounts receivable from one accounting period to the next. A positive number indicates an increase in receivables, while a negative number indicates a decrease.Change In Cash
Most indicators from Hookipa Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Hookipa Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.At this time, Hookipa Pharma's Tax Provision is quite stable compared to the past year. Issuance Of Capital Stock is expected to rise to about 57.8 M this year, although the value of Selling General Administrative will most likely fall to about 15.8 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 898K | 687K | 317K | 565.6K | Depreciation And Amortization | 4.6M | 3.6M | 3.6M | 2.9M |
Hookipa Pharma fundamental ratios Correlations
Click cells to compare fundamentals
Hookipa Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Hookipa Pharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 143.7M | 187.8M | 126.0M | 170.5M | 161.3M | 146.4M | |
Short Long Term Debt Total | 10.6M | 10.5M | 10.6M | 6.5M | 6.6M | 8.3M | |
Other Current Liab | 8.4M | 6.4M | 11.6M | 13.4M | 14.4M | 9.4M | |
Total Current Liabilities | 14.8M | 21.1M | 27.7M | 35.6M | 42.0M | 25.1M | |
Total Stockholder Equity | 117.9M | 156.1M | 89.6M | 102.5M | 89.9M | 87.6M | |
Other Liab | 1.9M | 1.9M | 2.7M | 29.1M | 33.4M | 35.1M | |
Net Tangible Assets | 117.9M | 156.1M | 89.6M | 102.5M | 117.9M | 66.6M | |
Property Plant And Equipment Net | 14.6M | 14.0M | 22.1M | 22.0M | 13.2M | 14.7M | |
Current Deferred Revenue | 3.6M | 4.6M | 6.2M | 16.0M | 14.7M | 8.4M | |
Net Debt | (102.6M) | (132.7M) | (56.3M) | (106.9M) | (110.5M) | (116.1M) | |
Retained Earnings | (103.0M) | (147.1M) | (222.8M) | (287.7M) | (369.3M) | (350.8M) | |
Accounts Payable | 944K | 8.0M | 8.8M | 5.5M | 12.5M | 6.4M | |
Cash | 113.2M | 143.2M | 66.9M | 113.4M | 117.1M | 104.3M | |
Non Current Assets Total | 15.7M | 16.3M | 23.9M | 23.3M | 14.2M | 16.2M | |
Non Currrent Assets Other | 1.1M | 1.9M | 1.4M | 863K | 1.0M | 1.3M | |
Other Assets | 1.1M | 10.1M | 1.8M | 1.3M | 1.0 | 0.95 | |
Long Term Debt | 3.5M | 4.5M | 2.2M | 911K | 819.9K | 778.9K | |
Cash And Short Term Investments | 113.2M | 143.2M | 66.9M | 113.4M | 117.1M | 104.3M | |
Net Receivables | 9.7M | 20.7M | 21.2M | 22.0M | 19.3M | 16.4M | |
Common Stock Shares Outstanding | 17.9M | 2.6M | 3.3M | 6.6M | 9.5M | 8.3M | |
Long Term Debt Total | 3.9M | 4.5M | 2.2M | 911K | 819.9K | 778.9K | |
Liabilities And Stockholders Equity | 143.7M | 187.8M | 126.0M | 170.5M | 161.3M | 146.4M | |
Non Current Liabilities Total | 11.1M | 10.6M | 8.8M | 32.3M | 29.5M | 24.4M | |
Capital Surpluse | 225.6M | 309.3M | 317.1M | 397.3M | 457.0M | 230.1M | |
Other Current Assets | 13.3M | 8.1M | 15.0M | 12.7M | 10.7M | 11.1M | |
Other Stockholder Equity | 81.8M | 309.3M | 317.1M | 397.3M | 467.0M | 264.5M | |
Total Liab | 25.8M | 31.7M | 36.5M | 67.9M | 71.5M | 42.7M | |
Net Invested Capital | 122.6M | 160.7M | 94.6M | 105.0M | 91.0M | 91.7M | |
Property Plant And Equipment Gross | 14.6M | 14.0M | 28.5M | 29.8M | 23.0M | 18.5M | |
Total Current Assets | 128.0M | 171.5M | 102.1M | 147.2M | 147.1M | 130.2M | |
Accumulated Other Comprehensive Income | (4.7M) | (6.1M) | (4.8M) | (7.2M) | (7.9M) | (8.3M) | |
Non Current Liabilities Other | 2.2M | 1.4M | 2.6M | 31.4M | 6.0M | 8.0M | |
Net Working Capital | 113.3M | 150.4M | 74.5M | 111.6M | 105.1M | 105.0M | |
Property Plant Equipment | 14.6M | 14.0M | 16.4M | 18.0M | 20.7M | 13.0M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.67) | Revenue Per Share 4.403 | Quarterly Revenue Growth (0.52) | Return On Assets (0.20) | Return On Equity (0.49) |
The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.